Starter en tråd om ExpreS2ion Biotech Holding AB (EXPRS2.ST) siden en del har den i favoritt-listen eller i porteføljen sin
ExpreS2ion Biotech Holding AB, through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops a platform technology that enables the production of complex proteins for new vaccines and diagnostics of malaria and zika. It specializes in developing cell lines and processes based on Drosophila S2 cells.
The company using its patented ExpreS2 platform, a proprietary S2 recombinant protein expression platform, produces proteins in collaboration with research institutions and biopharmaceutical companies. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools, which provide high-protein expression levels without selection pressure.
The company offers the ExpreS2 kit that includes ExpreS2 plasmids, ExpreS2 cells, ExpreS2 transfection reagents, culture media for S2 cells, and plasmid maps and protocols for use. It also offers ExpreS2 TR, a transfection reagent, which is formulated and optimized for insect cell transfection.
The company licenses ExpreS2 for use in biopharmaceutical research and development, and commercial protein manufacturing. ExpreS2ion Biotech Holding AB is based in Horsholm, Denmark.